Compare AbCellera Biologics Inc (ABCL) vs PayPal Holdings, Inc. (PYPL) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

PayPal trades at $45.65, up 0.4% with a bullish technical outlook. The stock appears undervalued with a P/E of 8.46 and strong profitability metrics including 15% net income margin and 25.12% ROE. Recent earnings beat expectations in Q1 2026, and the company maintains robust cash flow generation of $6.4B from operations. Analyst consensus is mixed with 37% buy ratings but a $49 price target suggesting 7% upside potential.

PayPal presents a value opportunity with attractive valuation multiples and solid fundamentals, though growth moderation and competitive pressures remain concerns. The stock's technical strength and dividend initiation provide support, while legal scrutiny and execution risks warrant monitoring. Upside appears limited near-term but long-term prospects remain favorable if management delivers on growth initiatives.